Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a weekly shot of pemvidutide or placebo ...
Jerry Durso, Altimmune CEO July 28, 2026 07:00 AM EDT R&D Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism Elizabeth Cairns Senior biopharma journalist Altimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that